摘要:
Methods are disclosed for inspecting a cylindrical porous ceramic body by positioning a diffuser near, and spaced apart from, the first end of a ceramic body; flowing a tracer flow toward the diffuser, wherein a first portion of the tracer flow passes through the diffuser, and a second portion of the tracer flow does not pass through the diffuser, the first and second portions of the tracer flow then entering the first end of the ceramic body, wherein the average velocity of the first portion of the tracer flow entering the ceramic body VAVG1 is lower than the average velocity of the second portion of the tracer flow entering the ceramic body VAVG2; directing light toward the second end of the ceramic body; and detecting reflected light coming from a location proximate the second transverse face at the second end of the ceramic body.
摘要:
Compounds of formula III: wherein R5a, R3, X, Y, Q, R1a and R1b are as defined in the specification, pharmaceutically acceptable salts thereof, and methods of use thereof.
摘要:
In a linear guide apparatus, a rolling-element accommodation belt 50 is incorporated into each of endless circulation passages. This rolling-element accommodation belt 50 is formed into a shape having ends and has a plurality of rolling-element accommodation sections for individually accommodating balls 46. Of the rolling-element accommodation sections, first rolling-element accommodation sections 55A located at the respective end sections are formed so as to constrain movement of a spacer section 59 located at the end section toward the outer periphery side of an endless circulation passage by means of the ball 46 accommodated in the spacer section. Second rolling-element accommodation sections 55B other than the first rolling-element accommodation sections are formed so as to enable removable accommodation of the balls 46 to be accommodated toward the inner periphery side of the endless circulation passage.
摘要:
A compound having Formula I: or a pharmaceutically acceptable salt thereof, wherein X, R, R and R are as defined in the specification; pharmaceutical compositions thereof; and methods of use thereof. The compounds of Formula I are inhibitors of Casein kinase II (CK2) pathways.
摘要:
Compounds of the invention are disclosed, such as compounds of formulae LX-LXIV, and pharmaceutically acceptable salts, isomers, or prodrugs thereof, which are useful as modulators of the activity of liver X receptors (LXR) and Farnesoid X receptors (FXR), where R00, R200, R400, R500, J11, J21, G1, G21, and Q are defined herein. Pharmaceutical compositions containing the compounds and methods of using the compounds are also disclosed.
摘要:
The present invention provides compounds for modulating protein kinase enzymatic activity for modulating cellular activities such as proliferation, differentiation, programmed cell death, migration and chemoinvasion. More specifically, the invention provides oxindole derivatives which inhibit, regulate and/or modulate kinase receptor, particularly VEGF receptor 2 (Flk-1/KDR), FGFR1, and PDGFR (alpha and beta), signal transduction pathways related to the changes in cellular activities as mentioned above, compositions which contain these compounds, and methods of using them to treat kinase-dependent diseases and conditions.
摘要:
The present invention relates to a process for the polymerization of olefins, comprising the steps of introducing at least one olefin, at least one polymerization catalyst, at least one cocatalyst and at least one cocatalyst aid, and optionally a scavenger, into a polymerization reactor, and polymerizing the olefin, wherein the cocatalyst aid is a reaction product prepared separately prior to the introduction into the reactor by reacting at least one metal alkyl compound of group IIA or IIIA of the periodic system of elements and at least one compound (A) of the formula RmXR′n, wherein R is a branched, straight, or cyclic, substituted or unsubstituted, hydrocarbon group having 1 to 30 carbon atoms, R′ is hydrogen or any functional group with at least one active hydrogen, X is at least one heteroatom selected from the group of O, N, P or S or a combination thereof, and wherein n and m are each at least 1 and are such that the formula has no net charge.
摘要:
A method of removing a restriction in a tubular located in a well includes providing a drilling assembly with a drill bit and a reamer, the reamer having a cutting structure for removing the restriction; drilling through a lower portion of the tubular; expanding the reamer at a location below the restriction; and urging the reamer back toward the restriction to remove the restriction.
摘要:
Pharmaceutical compositions suitable for oral administration in solid dosage forms are described. The compositions comprise an effective amount of a drug compound in the form of a salt, wherein the drug salt is characterized by conversion to a less soluble form of the drug compound under certain pH conditions, and an anti-nucleating agent.
摘要:
A mechanical latch assembly includes a supporting frame, a locking latch, an actuation arrangement and a safety lock arrangement. The locking latch is slidably mounted on the supporting frame in longitudinally movable manner. The actuation arrangement includes an actuation handle pivotally connected to the supporting frame to longitudinally drive the locking latch moving between a locked position an unlocked position. Moreover, the safety lock arrangement includes a locker member movably mounted on the supporting frame, wherein the locker member has a slider slot formed thereon to define a pusher surface and an opposed retracting surface, and a thermal activated arm substantially extended from the supporting frame to slidably pass through the slider slot of the locker member at a safety temperature, and adapted to deflect to push the locker member at the pusher surface at an elevated operation temperature.